CSPC Megalith Biopharmaceutical has entered into a license agreement with Radiance Biopharma for the development and ...

Japanese drugmaker Chugai Pharmaceutical today announced gaining regulatory approval from the Ministry of Health, Labor and ...

Sweden’s BioArctic today revealed that the US Federal Trade Commission (FTC) has cleared the proposed deal with Bristol Myers ...

Hong Kong-based Ascletis Pharma announced today positive interim results from the first two cohorts of its randomized, double ...

US CNS specialist Supernus Pharmaceuticals has announced that its Phase IIb study of SPN-820 in adults with ...

Eleva, a German company developing difficult-to-produce biologics based on a breakthrough moss-based platform, has announced the appointment of Martin Bauer as its chief medical officer (CMO).

Swiss drug developer Basilea Pharmaceutica yesterday announced its results for the financial year ended December 31, 2024.

The International Generic and Biosimilar Medicines Association (IGBA), in line with its goals of promoting the widest possible access to safe, effective, and quality-assured medicines and of promoting ...

New Jersey, USA-based Imunon announced new translational data from the Phase II OVATION 2 Study of IMNN-001, an ...

In a U-turn for the UK health technology assessor, the National Institute for Health and Care Excellence (NICE) has today ...

Privately-held Ventus Therapeutics, a biopharma with two novel small-molecule programs entering Phase II development for ...

Germany-based Bayer’s wholly-owned gene therapy company AskBio today announced that its investigational gene therapy AB-1005 ...